GlycoMimetics is a renowned late-stage biotechnology company specializing in the discovery and development of cutting-edge therapies for cancers and inflammatory diseases based on the field of glycobiology. At GlycoMimetics, we use our expertise in the role of carbohydrates in cell recognition and our proprietary chemistry platform to create innovative medicines that aim to enhance patient outcomes. Our lead candidate, uproleselan, is currently in pivotal Phase 3 development for relapsed/refractory acute myeloid leukemia (AML).

It has also received Breakthrough Therapy and Fast Track designations from the U. S. FDA for adult AML patients with relapsed or refractory disease.

Uproleselan is an investigational first-in-class E-selectin antagonist. In addition to uproleselan, our pipeline includes other promising candidates, such as GMI-1687 and Galectin Antagonists, which hold great potential in the field of glycobiology. We actively engage in collaborations with leading academics, government organizations, and pharmaceutical/biotechnology companies to drive our proprietary programs forward and ensure the success of our business.

Contact GlycoMimetics today to learn more about our groundbreaking work and contribute to the advancement of innovative therapies in the field of glycobiology